These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6399071)

  • 21. Evaluation of the activity of streptomycin on Mycobacterium leprae in mice.
    Pattyn SR; Saerens E
    Lepr Rev; 1978 Dec; 49(4):275-81. PubMed ID: 368476
    [No Abstract]   [Full Text] [Related]  

  • 22. Activity of four clofazimine analogues against Mycobacterium leprae.
    Levy L
    Lepr Rev; 1981 Mar; 52(1):23-6. PubMed ID: 7017318
    [No Abstract]   [Full Text] [Related]  

  • 23. [Preliminary observation on the effect of thymic peptide in the experimental infection of mice with mycobacterium leprae].
    Wang HY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Jun; 7(3):227-8. PubMed ID: 2939979
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of the multiplication of Mycobacterium leprae by methimazole.
    Levy L; Moon N
    Am Rev Respir Dis; 1972 Dec; 106(6):917-20. PubMed ID: 4565731
    [No Abstract]   [Full Text] [Related]  

  • 25. The mouse foot-pad technique for cultivation of Mycobacterium leprae.
    Levy L; Ji B
    Lepr Rev; 2006 Mar; 77(1):5-24. PubMed ID: 16715686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae.
    Pattyn SR; Hébrant F
    Arzneimittelforschung; 1980; 30(12):2099-103. PubMed ID: 7011330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA
    Indian J Lepr; 1995; 67(4):375-82. PubMed ID: 8849914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Acetylpyridine thiosemicarbazones and Mycobacterium leprae.
    Shepard CC; Klayman DL; Scovill JP; Morrison NE
    Int J Lepr Other Mycobact Dis; 1984 Mar; 52(1):7-9. PubMed ID: 6368429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beige mice infected with Mycobacterium leprae.
    Gelber RH; Scollard DM; Cynamon MH
    Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):295-7. PubMed ID: 7602228
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary dapsone-resistant leprosy in Cebu, Philippines.
    Guinto RS; Cellona RV; Fajardo TT; de la Cruz EC
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):427-30. PubMed ID: 7042607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacterial growth kinetics of "M. lufu" in the presence and absence of various drugs alone and in combination. A model for the development of combined chemotherapy against M. leprae?
    Seydel JK; Wempe EG
    Int J Lepr Other Mycobact Dis; 1982 Mar; 50(1):20-30. PubMed ID: 7042611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hsp65 DNA vaccination carrying immunostimulatory DNA sequences (CpG motifs) against Mycobacterium leprae multiplication in mice.
    Nomaguchi H; Mukai T; Takeshita F; Matsuoka M; Maeda Y; Aye TM; Jahan N; Yogi Y; Endo M; Sato Y
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):182-90. PubMed ID: 12483966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice.
    Saito H; Tomioka H; Sato K; Dekio S
    Int J Lepr Other Mycobact Dis; 1994 Mar; 62(1):43-7. PubMed ID: 8189088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice.
    Tomioka H; Saito H
    Int J Lepr Other Mycobact Dis; 1993 Jun; 61(2):250-4. PubMed ID: 8396614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980].
    Guelpa-Lauras CC; Constant-Desportes M; Millan J; Grosset J
    Acta Leprol; 1982; (86-87):77-80. PubMed ID: 6816000
    [No Abstract]   [Full Text] [Related]  

  • 36. Dosage and site of entry influence growth and dissemination of Mycobacterium leprae in T900r mice.
    Ebenezer GJ; Arumugam S; Job CK
    Int J Lepr Other Mycobact Dis; 2002 Dec; 70(4):245-9. PubMed ID: 12768925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viability of Mycobacterium leprae in skin and peripheral nerves and persistence of nerve destruction in multibacillary patients after 2 years of multidrug therapy.
    Job CK; Jayakumar J; Aschhoff M; Mathan MM
    Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):44-50. PubMed ID: 8627112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prothionamide and prothionamide-S-oxide in experimental leprosy.
    Matsuo Y; Tatsukawa H; Murray JF; Peters JH
    Int J Lepr Other Mycobact Dis; 1981 Sep; 49(3):302-6. PubMed ID: 6459296
    [No Abstract]   [Full Text] [Related]  

  • 39. [Protective properties of M. lufu in experimental leprosy].
    Iushin MIu; Kalianina OV
    Probl Tuberk; 1995; (2):47-8. PubMed ID: 7777465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifampicin resistant leprosy: a review and a research proposal of a pilot study.
    Ji B
    Lepr Rev; 2002 Mar; 73(1):2-8. PubMed ID: 11969122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.